Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RDY
stocks logo

RDY

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
88.11B
+9.92%
19.089
+14.33%
84.87B
+1.54%
18.311
+15.71%
Estimates Revision
The market is revising Upward the revenue expectations for Dr. Reddy's Laboratories Limited (RDY) for FY2026, with the revenue forecasts being adjusted by 0.71% over the past three months. During the same period, the stock price has changed by -0.79%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.71%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-4.02%
In Past 3 Month
Stock Price
Go Down
down Image
-0.79%
In Past 3 Month
2 Analyst Rating
up Image0
Wall Street analysts forecast RDY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDY is 16.20 USD with a low forecast of 15.50 USD and a high forecast of 16.90  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
up Image0
Current: 13.820
sliders
Low
15.50
Averages
16.20
High
16.90
up Image0
Current: 13.820
sliders
Low
15.50
Averages
16.20
High
16.90
HSBC
Hold
to
Buy
upgrade
2025-06-05
Reason
HSBC
Price Target
2025-06-05
upgrade
Hold
to
Buy
Reason
HSBC upgraded Dr. Reddy's to Buy from Hold with a price target of $16.90, up from $14.44. The firm believes semaglutide sales will help Dr. Reddy's to return to earnings growth path within a year of launch in key markets. While a recent court order in India has restrained Dr. Reddy's launch of semaglutide in export markets until the patent expiry of the reference brand in India in March 2026, the company will be among the first companies to launch in key markets opening up in 2026, the analyst tells investors in a research note. The firm sees a semaglutide-led earnings recovery for the company.
Barclays
Balaji Prasad
Buy
Maintains
$17 → $17
2024-11-06
Reason
Barclays
Balaji Prasad
Price Target
$17 → $17
2024-11-06
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dr Reddy's Laboratories Ltd (RDY.N) is 18.56, compared to its 5-year average forward P/E of 20.96. For a more detailed relative valuation and DCF analysis to assess Dr Reddy's Laboratories Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
20.96
Current PE
18.56
Overvalued PE
25.60
Undervalued PE
16.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
12.76
Current EV/EBITDA
11.91
Overvalued EV/EBITDA
15.26
Undervalued EV/EBITDA
10.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
3.28
Current PS
2.91
Overvalued PS
3.68
Undervalued PS
2.87

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

RDY News & Events

Events Timeline

(ET)
2025-06-05
07:07:43
Alvotech, Dr. Reddy's enter pact to codevelop biosimilar candidate to Keytruda
select
2025-04-14 (ET)
2025-04-14
13:48:41
Dr. Reddy's says report of 25% workforce cost reduction 'incorrect'
select
2025-04-14
13:38:40
Dr. Reddy's says report of 25% workforce cost reduction 'incorrect'
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-30NASDAQ.COM
Relative Strength Alert For Dr. Reddy's Laboratories

  • Dr. Reddy's Laboratories Stock Performance: Dr. Reddy's Laboratories Ltd. shares have entered oversold territory with an RSI of 27.0, indicating potential buying opportunities as the stock trades around $14 per share, compared to its 52-week low of $12.26 and high of $16.892.

  • Market Comparison: The current RSI for the S&P 500 ETF is significantly higher at 71.1, suggesting that RDY's recent heavy selling may be nearing exhaustion, prompting bullish investors to consider entry points.

Preview
9.5
07-24Newsfilter
Dr. Reddy's Q1FY26 Financial Results

  • Financial Performance Overview: Dr. Reddy's Laboratories reported consolidated revenues of ₹85.5 billion for Q1 FY26, reflecting an 11% year-over-year growth but flat compared to the previous quarter. Key metrics included a gross margin of 56.9%, EBITDA of ₹22.8 billion, and profit after tax attributable to equity holders at ₹14.2 billion.

  • Market Insights and Strategic Developments: The company highlighted strong performance in branded markets and its Nicotine Replacement Therapy portfolio, while facing pricing pressures in the U.S. generics market. Notable collaborations were announced, including partnerships with Alvotech and Sanofi for biosimilars and new drug launches.

Preview
5.0
07-23SeekingAlpha
Dr. Reddy’s to launch generic semaglutide in 87 countries: Bloomberg

  • Dr. Reddy's Generic Launch: Dr. Reddy’s Laboratories plans to launch a generic version of semaglutide, the active ingredient in Novo Nordisk’s Wegovy, in 87 countries starting in 2026, as global patents expire and regulatory submissions are already in progress.

  • Market Strategy and Revenue Potential: The company aims to adopt tiered pricing strategies for broader access and anticipates that semaglutide could generate significant revenue, with plans to introduce up to 26 GLP-1 therapies over the next decade.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY) stock price today?

The current price of RDY is 13.82 USD — it has increased 0.14 % in the last trading day.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY)'s business?

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

arrow icon

What is the price predicton of RDY Stock?

Wall Street analysts forecast RDY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDY is 16.20 USD with a low forecast of 15.50 USD and a high forecast of 16.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY)'s revenue for the last quarter?

Dr Reddy's Laboratories Ltd revenue for the last quarter amounts to 998.90M USD, increased 8.58 % YoY.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY)'s earnings per share (EPS) for the last quarter?

Dr Reddy's Laboratories Ltd. EPS for the last quarter amounts to 0.20 USD, decreased 0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dr Reddy's Laboratories Ltd (RDY)'s fundamentals?

The market is revising Upward the revenue expectations for Dr. Reddy's Laboratories Limited (RDY) for FY2026, with the revenue forecasts being adjusted by 0.71% over the past three months. During the same period, the stock price has changed by -0.79%.
arrow icon

How many employees does Dr Reddy's Laboratories Ltd (RDY). have?

Dr Reddy's Laboratories Ltd (RDY) has 27811 emplpoyees as of August 12 2025.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY) market cap?

Today RDY has the market capitalization of 11.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free